| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0082 | 0.8 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |